HomeAbout usHospitalsSearchLogin
Your medical data, safe and secure.
Name
HGS-TR2J
Description
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
No brand information found.
